Appraising osteoporosis care gaps

Rheumatology International

Volumn 32, Issue 11, 2012, Pages 3619-3624

  Olenginski, Thomas P ^a   Antohe, Jana L ^a   Sunderlin, Elaine ^b   Harrington, Thomas M ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; DXA; Fracture risk; Glucocorticoid induced osteoporosis program; Osteoporosis; Osteoporosis care gap; Treatment adherence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SELF EVALUATION; UNSPECIFIED SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84872202161     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2203-5     Document Type: Article

References (37)

1. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King AB, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States. J Bone Miner Res 22:465-475 (Pubitemid 46797130)
2. Dawson-Hughes B, Tosteson A, Melton LJ et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis Int. doi: 10.1007/s00198-008-0559-5
3. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
4. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541 (Pubitemid 26411651)
5. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280:2077-2082 (Pubitemid 29014065)
6. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91 (Pubitemid 30099515)
7. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352 (Pubitemid 29483192)
8. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249 (Pubitemid 41094364)
9. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial: multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637-645 (Pubitemid 29384151)
10. Chestnut CH III, Silverman S, Andriano K et al (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 109:267-276
11. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM 344: 1434-1441 (Pubitemid 32402100)
12. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM 356:1809-1822 (Pubitemid 46698462)
13. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthr Rheum 35:293-305
14. Rosen CJ, Brown SA (2005) A rationale approach to evidence gaps in the management of osteoporosis. Am J Med 118:1183-1189 (Pubitemid 41566516)
15. Majumdar SR, Kim N, Colman I et al (2005) Incidental vertebral fractures discovered with chest radiography in the emergency department. Arch Intern Med 165:905-909
16. Andrade SE, Majumdar SR, Chan A et al (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052-2057 (Pubitemid 37151247)
17. Cuddihy MT, Gabriel SE, Crowson CS et al (2002) Osteoporosis intervention following distal forearm fractures. Arch Intern Med 162:421-426 (Pubitemid 34150643)
18. Pullman-Mooar S, Mooar P (2005) Osteoporosis treatment after hip fracture: slow progress. J Clin Rheumatol 11:65-66
19. Kamel HK (2005) Secondary prevention of hip fractures among the hospitalized elderly -Are we doing enough? J Clin Rheumatol 11:68-71 (Pubitemid 40577949)
20. Majumdar SR, Beaupre LA, Harley CH et al (2007) Use of a case manager to improve osteoporosis treatment after hip fracture. Arch Intern Med 167:2110-2115
21. Kaufman JD, Bolander ME, Bunta AD et al (2003) Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg 85:1837-1843 (Pubitemid 37129626)
22. Felstein A, Elmer PJ, Orwoll E, Herson M, Hillier T (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures. Arch Intern Med 163:2165-2172
23. Crilly RG, McKercher HG, Hindman D, Pavlakovic R, Kloseck M (2003) Prevention of fractures in the long-Term care population: the gap between evidence and practice, Geriatrics Today. J Can Geriatr Soc 6:16-20 (Pubitemid 36514223)
24. McNearney TA, Shepherd AJ, Chhabra A, Goel N (2006) Primary care house staff attitudes toward osteoporosis management. South Med J 99:461-466 (Pubitemid 43804514)
25. Juby AG, De Geus-Wenceslau CM (2002) Evaluation of osteoporosis treatment in seniors after hip fracture. Osteoporos Int 13:205-210 (Pubitemid 34408186)
26. Papaioannou A, Kennedy C, Ioannidis G et al (2008) The osteoporosis care gap in men with fragility fractures: the Canadian multicentre osteoporosis study. Osteoporos Int 19:581-587
27. Newman ED, Starkey R, Ayoub W, Gutknecht D, Hanus P, Davis C, Diehl J, Neuner M (2000) Osteoporosis clinical practice guideline, 2nd edn. Penn State Geisinger Health System, USA
28. Newman ED, Olenginski TP, Perruquet JL, Hummel J, Indeck C, Wood GC (2004) Using mobile DXA to improve access to osteoporosis care. J Clin Densitom 7:71-75 (Pubitemid 38223467)
29. National Osteoporosis Foundation (2003) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
30. Solomon DH, Morris C, Cheng H et al (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80:194-202 (Pubitemid 40194534)
31. Bloui J, Dragomir A, Ste-Marie L-G, Fernandes JC, Perreault S (2007) Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J Clin Endocrinol Metab 92:887-894 (Pubitemid 46465659)
32. Baim S (2008) Official positions of the International society for clinical densitometry and executive summary of the 2007 ISCD position development conference. J Clin Densitom 11:75-91 (Pubitemid 351602189)
33. Olenginski TP, Newman ED, Hummel JL, Hummer M (2006) Development and evaluation of a vertebral fracture assessment program using IVA and its integration with Mobile DXA. J Clin Densitom 9:72-77 (Pubitemid 43775506)
34. Stock JL, Waud CE, Coderre JA et al (1998) Clinical reporting to primary care physicians leads to increased use and understanding of bone densitometry and affects the management of osteoporosis. Ann Int Med 128:996-999 (Pubitemid 28275176)
35. Tannenbaum C, Clark J, Schwartzman K et al (2002) Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431-4437 (Pubitemid 35247019)
36. Holick M (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81(3):353-373 (Pubitemid 43334631)
37. Newman ED, Matzko CK, Olenginski TP et al (2006) Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful program with improved outcomes at 1 year. Osteoporos Int 17:1428-1434 (Pubitemid 44127331)